Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only

Cellular Oncology

Volumn 35, Issue 2, 2012, Pages 119-126

  Ottenhof, Niki A ^a,b   Morsink, Folkert H M ^a   Kate, Fiebo Ten ^a   Van Noorden, Cornelis J F ^b   Offerhaus, G Johan A ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Immunohistochemistry; Long term survival; Lymph node ratio; Pancreatic ductal adenocarcinoma; Prognosis; Resection margin; Smad4

Indexed keywords

ALDEHYDE DEHYDROGENASE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN AXL; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; PROTEIN TYROSINE KINASE; SMAD4 PROTEIN; UNCLASSIFIED DRUG; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ISOENZYME; RETINAL DEHYDROGENASE; SMAD4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; CANCER STAGING; ENZYMOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETINAL DEHYDROGENASE; SMAD4 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866746447     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-012-0072-x     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun, Cancer statistics, 2009. CA Cancer J Clin 59, 225-49 (2009)
2. A. Maitra, S.E. Kern, R.H. Hruban, Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 20, 211-26 (2006)
3. G. Schneider, J.T. Siveke, F. Eckel, R.M. Schmid, Pancreatic cancer: basic and clinical aspects. Gastroenterology 128, 1606-25 (2005) (Pubitemid 40692555)
4. C.C. Hsu, J.M. Herman, M.M. Corsini, J.M. Winter, M.D. Callister, M.G. Haddock, J.L. Cameron, T.M. Pawlik, R.D. Schulick, C.L. Wolfgang, D.A. Laheru,M.B. Farnell, M.J. Swartz, L.L. Gunderson, R.C. Miller, Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 17, 981-90 (2010)
5. M. David, C. Lepage, J.L. Jouve, V. Jooste, M. Chauvenet, J. Faivre, A.M. Bouvier, Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer 101, 215-8 (2009)
6. T. Schnelldorfer, A.L. Ware, M.G. Sarr, T.C. Smyrk, L. Zhang, R. Qin, R.E. Gullerud, J.H. Donohue, D.M. Nagorney, M.B. Farnell, Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247, 456-62 (2008)
7. C.R. Ferrone, M.F. Brennan, M. Gonen, D.G. Coit, Y. Fong, S. Chung, L. Tang, D. Klimstra, P.J. Allen, Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12, 701-6 (2008)
8. G. Barugola, S. Partelli, S. Marcucci, N. Sartori, P. Capelli, C. Bassi, P. Pederzoli, M. Falconi, Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol 16, 3316-22 (2009)
9. M.H. Katz, H. Wang, J.B. Fleming, C.C. Sun, R.F. Hwang, R.A. Wolff, G. Varadhachary, J.L. Abbruzzese, C.H. Crane, S. Krishnan, J.N. Vauthey, E.K. Abdalla, J.E. Lee, P.W. Pisters, D. B. Evans, Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16, 836-47 (2009)
10. S.A. Hahn, M. Schutte, A.T. Hoque, C.A. Moskaluk, L.T. da Costa, E. Rozenblum, C.L. Weinstein, A. Fischer, C.J. Yeo, R.H. Hruban, S.E. Kern, DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-3 (1996)
11. A. Blackford, O.K. Serrano, C.L. Wolfgang, G. Parmigiani, S. Jones, X. Zhang, D.W. Parsons, J.C. Lin, R.J. Leary, J.R. Eshleman, M. Goggins, E.M. Jaffee, C.A. Iacobuzio-Donahue, A. Maitra, J.L. Cameron, K. Olino, R. Schulick, J.Winter, J.M. Herman, D. Laheru, A.P. Klein, B. Vogelstein, K.W. Kinzler, V.E. Velculescu, R.H. Hruban, SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 15, 4674-9 (2009)
12. B. Nakata, Y.Q. Wang, M. Yashiro, N. Nishioka, H. Tanaka, M. Ohira, T. Ishikawa, H. Nishino, K. Hirakawa, Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res 8, 2536-40 (2002) (Pubitemid 34856337)
13. M. Goggins, G.J. Offerhaus, W. Hilgers, C.A. Griffin, M. Shekher, D. Tang, T.A. Sohn, C.J. Yeo, S.E. Kern, R.H. Hruban, Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 152, 1501-7 (1998) (Pubitemid 28275008)
14. J.T. Maple, T.C. Smyrk, L.A. Boardman, R.A. Johnson, S.N. Thibodeau, S.T. Chari, Defective DNA mismatch repair in longterm (> or 03 years) survivors with pancreatic cancer. Pancreatology 5, 220-7 (2005). discussion 227-8 (Pubitemid 40754740)
15. J.B. Koorstra, C.A. Karikari, G. Feldmann, S. Bisht, P.L. Rojas, G. J. Offerhaus, H. Alvarez, A. Maitra, The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8, 618-26 (2009)
16. Song, X., Wang, H., Logsdon, C.D., Rashid, A., Fleming, J.B., Abbruzzese, J.L., Gomez, H.F., Evans, D.B.,Wang, H.: Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer (2010)
17. Z.A. Rasheed, J. Yang, Q. Wang, J. Kowalski, I. Freed, C. Murter, S.M. Hong, J.B. Koorstra, N.V. Rajeshkumar, X. He, M. Goggins, C. Iacobuzio-Donahue, D.M. Berman, D. Laheru, A. Jimeno, M. Hidalgo, A. Maitra, W. Matsui, Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 102, 340-51 (2010)
18. A.N. Milne, R. Sitarz, R. Carvalho, F. Carneiro, G.J. Offerhaus, Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. Curr Mol Med 7, 15-28 (2007) (Pubitemid 46322276)
19. A. Maitra, N.V. Adsay, P. Argani, C. Iacobuzio-Donahue, A. De Marzo, J.L. Cameron, C.J. Yeo, R.H. Hruban, Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16, 902-12 (2003) (Pubitemid 37152020)
20. F. Bergmann, S. Aulmann, M.N. Wente, R. Penzel, I. Esposito, J. Kleeff, H. Friess, P. Schirmacher, Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol 59, 580-4 (2006) (Pubitemid 43886040)
21. G. Butturini, D.D. Stocken, M.N.Wente, H. Jeekel, J.H. Klinkenbijl, K.E. Bakkevold, T. Takada, H. Amano, C. Dervenis, C. Bassi, M.W. Buchler, J.P. Neoptolemos, Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 143, 75-83 (2008). discussion 83 (Pubitemid 351159303)
22. I. Bhatti, O. Peacock, A.K. Awan, D. Semeraro, M. Larvin, R.I. Hall, Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg 34, 768-75 (2010)
23. H. Riediger, T. Keck, U. Wellner, A. zur Hausen, U. Adam, U.T. Hopt, F. Makowiec, The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 13, 1337-44 (2009)
24. T.M. Pawlik, A.L. Gleisner, J.L. Cameron, J.M. Winter, L. Assumpcao, K.D. Lillemoe, C. Wolfgang, R.H. Hruban, R.D. Schulick, C.J. Yeo, M.A. Choti, Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 141, 610-8 (2007) (Pubitemid 46616937)
25. Showalter, T.N.,Winter, K.A., Berger, A.C., Regine,W.F., Abrams, R. A., Safran, H., Hoffman, J.P., Benson, A.B., Macdonald, J.S., Willett, C.G.: The Influence of Total Nodes Examined, Number of Positive Nodes, and Lymph Node Ratio on Survival after Surgical Resection and Adjuvant Chemoradiation for Pancreatic Cancer: A Secondary Analysis of RTOG 9704. Int J Radiat Oncol Biol Phys (2010)
26. C. Ghimenti, P. Tannergard, S. Wahlberg, T. Liu, P.G. Giulianotti, F. Mosca, G. Fornaciari, G. Bevilacqua, A. Lindblom, M.A. Caligo, Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours. Br J Cancer 80, 11-6 (1999) (Pubitemid 29210081)
27. T.A. Kunkel, D.A. Erie, DNA mismatch repair. Annu Rev Biochem 74, 681-710 (2005) (Pubitemid 40995521)
28. R.E. Wilentz, G.H. Su, J.L. Dai, A.B. Sparks, P. Argani, T.A. Sohn, C.J. Yeo, S.E. Kern, R.H. Hruban, Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 156, 37-43 (2000) (Pubitemid 30644436)
29. P. Chieco, A. Jonker, C.J.F. Van Noorden, Image cytometry, 1st edn. (BIOS Scientific Publishers, Oxford, 2001)